drug-resistance
CAGE (Cancer-Associated GEne) is a cancer/testis antigen first identified in the sera of gastric cancer patients. It has since been characterized across multiple cancer types as a driver of protective autophagy and anticancer drug resistance, acting through direct interactions with core autophagy machinery (such as Beclin1 and VPS34) and through transcriptional or microRNA-based regulatory loops involving downstream targets like HDAC9, S1PR1, and GSK3β.
Related terms
Source papers
- The CAGE–miR-181b-5p–S1PR1 Axis Regulates Anticancer Drug Resistance and Autophagy in Gastric Cancer Cells doi:10.3389/fcell.2021.666387
- Cancer/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma doi:10.1038/s41598-023-43124-8
- HDAC9 and miR-512 Regulate CAGE-Promoted Anti-Cancer Drug Resistance and Cellular Proliferation doi:10.3390/cimb46060311